BioWorld

Oct. 8, 2007

MAP's IPO Prices Lower Than Expected But Still Raises $60M

MAP Pharmaceuticals Inc. is adding $60 million through an initial public offering to support an upcoming Phase III trial of its late-stage aerosolized products for asthma and migraine. (BioWorld Today) Read More

Haptogen Acquisition Brings Shark Therapies To Wyeth

Academia May Be Suffering But Biotech Chugs Along

Targeting Cellular MicroRNA Can Flush HIV Out Of Hiding

Pfizer Launches Bay Area Biotech Innovation Center

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 24, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Illustration of tau accumulating in a neuron cell.

ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

BioWorld

ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...